Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals Inc (SLRX)
NASDAQ:SLRX
RESEARCH TOOLSreports
Total Valuation
Salarius Pharmaceuticals has a market cap or net worth of $1.50M. The enterprise value is $13.90M.
Market Cap$1.50M
Enterprise Value$13.90M
Share Statistics
Salarius Pharmaceuticals has 2,127,286 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,127,286
Owned by Insiders2.84%
Owned by Institutions0.72%
Financial Efficiency
Salarius Pharmaceuticals’s return on equity (ROE) is -3.69 and return on invested capital (ROIC) is -330.78%.
Return on Equity (ROE)-3.69
Return on Assets (ROA)-1.84
Return on Invested Capital (ROIC)-330.78%
Return on Capital Employed (ROCE)-3.79
Revenue Per Employee0.00
Profits Per Employee-2.79M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Salarius Pharmaceuticals is -0.32. Salarius Pharmaceuticals’s PEG ratio is >-0.01.
PE Ratio-0.32
PS Ratio0.00
PB Ratio2.50
Price to Fair Value1.17
Price to FCF-1.36
Price to Operating Cash Flow-1.48
PEG Ratio>-0.01
Income Statement
In the last 12 months, Salarius Pharmaceuticals had revenue of 0.00 and earned -5.58M in profits. Earnings per share was -5.79.
Revenue0.00
Gross Profit0.00
Operating Income-5.73M
Pretax Income-5.58M
Net Income-5.58M
EBITDA-5.57M
Earnings Per Share (EPS)-5.79
Cash Flow
In the last 12 months, operating cash flow was -4.35M and capital expenditures 0.00, giving a free cash flow of -4.35M billion.
Operating Cash Flow-4.35M
Free Cash Flow-4.35M
Free Cash Flow per Share-2.05
Dividends & Yields
Salarius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-80.47%
50-Day Moving Average0.74
200-Day Moving Average1.36
Relative Strength Index (RSI)40.83
Average Volume (3m)34.97K
Important Dates
Salarius Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Salarius Pharmaceuticals as a current ratio of 1.98, with Debt / Equity ratio of 0.00%
Current Ratio1.98
Quick Ratio1.98
Debt to Market Cap0.13
Net Debt to EBITDA0.40
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Salarius Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Salarius Pharmaceuticals EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.10.
EV to Sales0.00
EV to EBITDA0.08
EV to Free Cash Flow0.10
EV to Operating Cash Flow0.10
Balance Sheet
Salarius Pharmaceuticals has $1.80M in cash and marketable securities with $112.23K in debt, giving a net cash position of -$1.69M billion.
Cash & Marketable Securities$1.80M
Total Debt$112.23K
Net Cash-$1.69M
Net Cash Per Share-$0.79
Tangible Book Value Per Share$1.57
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Salarius Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast79.57%